Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

$35 Billion Market! Positive Clinical Trial! Yet Shares Are Down?

By Brian Orelli, PhD - Updated Apr 19, 2019 at 11:49AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here are four reasons Intercept stock is down despite positive data in the company's NASH trial.

In what was gearing up to be potentially the biggest binary event in 2019, Intercept Pharmaceuticals ( ICPT -8.28% ) released data on Tuesday for its late-stage Regenerate study, which was testing obeticholic acid (OCA) in patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH).

Shares shot up as much as 19% but settled to just a 6% gain on Tuesday, and they gave up all of that ground (and then some) on Wednesday, after investors had time to digest the data -- at least as much as was provided. We'll get more when the full results are presented at the European Association for the Study of the Liver 2019 International Liver Congress in April.

Patient with liver highlighted and a diagram of the parts of the liver

Image source: Getty Images.

With a clear unmet need in NASH -- there aren't any drugs approved to treat the disease -- and positive phase 3 data, it seems likely that Intercept will be able to get OCA, which is marketed as Ocaliva in another liver disease called primary biliary cholangitis, approved to treat NASH.

But Intercept's valuation will ultimately be set by how well OCA sells in NASH, and there are a few reasons why investors may be concerned enough to be hitting the sell button.

1. Not a cure

The Regenerate study had two main endpoints and the drug only had to hit one for the result to be positive. The higher dose clearly met one of the endpoints, improving patients' fibrosis by at least one stage with no worsening of NASH: 23.1% of patients taking the higher dose met the goal, compared to 11.9% of patients on placebo.

The trial also measured the ability of the drug to resolve NASH with no worsening of the stage of liver fibrosis, and while there was a numerical improvement, with 11.7% of patients taking the higher dose achieving the goal compared to 8% of patients receiving placebo, the difference wasn't statistically significant.

Resolving NASH was a large hurdle to clear in these midstage patients, and improving fibrosis should be enough to gain FDA approval, but a statistically significant improvement in NASH would clearly help convince doctors to prescribe the drug more frequently.

2. Big market (that will be broken up)

The NASH market is estimated to be as large as $35 billion in annual sales, but those numbers come from patients with NASH who are on a continuum of fibrosis from early stage 1 through 4, where cirrhosis of the liver sets in. Before NASH, patients are usually classified as having non-alcoholic fatty liver disease (NAFLD).

The Regenerate study had mostly patients with stage 2 and 3 fibrosis, but added some stage 1 patients who were included in a separate analysis. With those patients added, the fraction of patients who saw their fibrosis improve by at least one stage with no worsening of NASH went down from 23.1% in the aforementioned stage 2 and 3 patients to 21% of patients with stage 1-3. On the other hand, the second endpoint -- NASH resolution with no worsening of liver fibrosis stage -- improved from 11.7% of stage 2 and 3 patients to 14.9% of stage 1-3 patients.

How doctors will interpret the stage 1 data remains to be seen, but there's some evidence from doctors at the Karolinska Institutet in Sweden that fibrosis stage, but not NASH, predicts mortality in patients with NAFLD.

3. Side effects

More than half of patients taking the higher dose of the drug reported increased itching compared to just 19% of patients on placebo and 28% of patients on the lower dose. Most of those were mild to moderate, but severe itching, which resulted in patients being removed from the study, occurred in 5% of patients taking the higher dose versus less than 1% of those on placebo or the lower dose. In fact, 9% of patients discontinued due to itching (of any level).

Considering that NASH can eventually result in the need for a liver transplant, some added itching shouldn't be enough to keep the FDA from approving OCA for NASH, but it may dampen sales a bit if some patients find the side effect annoying enough.

Check out he latest Intercept Pharmaceuticals earnings call transcript.

4. Sell the news

Biotech investors may be selling simply because they're moving onto the next binary event. That could present an opportunity to get shares of Intercept on sale, but investors buying today will have to be patient. The company still has some number crunching to do before it can file for approval with the FDA and EU regulators in the second half of this year, setting up a likely approval in the first half of 2020.

Even then, given the lack of currently approved drugs for NASH, it could be slow going building a market of doctors who regularly diagnose and treat NASH. It'll take a while and multiple drugs treating the spectrum of patients to get to the $35 billion figure that analysts have predicted.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intercept Pharmaceuticals Stock Quote
Intercept Pharmaceuticals
ICPT
$15.63 (-8.28%) $-1.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.